Loading...
XPARABNX
Market cap43mUSD
Dec 23, Last price  
1.21EUR
1D
-2.42%
1Q
-6.92%
Jan 2017
-86.01%
IPO
-90.47%
Name

Abionyx Pharma SA

Chart & Performance

D1W1MN
XPAR:ABNX chart
P/E
—
P/S
9.04
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.38%
Rev. gr., 5y
92.84%
Revenues
5m
-11.65%
00000174,00000675,0005,252,0004,640,000
Net income
-4m
L-18.24%
-7,742,000-6,563,000-16,638,000-24,871,000-4,978,000-6,305,0001,849,000-1,886,000-5,830,000-4,303,000-3,518,000
CFO
-4m
L+10.09%
-14,493,000-3,303,000-13,711,000-19,197,000-9,092,000-6,001,000-3,950,000-599,000-6,692,000-3,359,000-3,698,000
Earnings
Feb 26, 2025

Profile

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.
URL
https://www.abionyx.com/en/
IPO date
Mar 30, 2015
Employees
62
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
4,640
-11.65%
5,252
678.07%
675
 
Cost of revenue
8,030
7,044
5,930
Unusual Expense (Income)
NOPBT
(3,390)
(1,792)
(5,255)
NOPBT Margin
Operating Taxes
97
8
Tax Rate
NOPAT
(3,390)
(1,889)
(5,263)
Net income
(3,518)
-18.24%
(4,303)
-26.19%
(5,830)
209.12%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,186
42
3,991
BB yield
Debt
Debt current
815
870
1,054
Long-term debt
4,358
5,250
6,556
Deferred revenue
Other long-term liabilities
412
417
504
Net debt
1,069
1,950
(439)
Cash flow
Cash from operating activities
(3,698)
(3,359)
(6,692)
CAPEX
(104)
(175)
(166)
Cash from investing activities
(130)
(175)
1,338
Cash from financing activities
3,886
(194)
3,972
FCF
(3,583)
(1,382)
(8,214)
Balance
Cash
4,104
4,046
7,935
Long term investments
124
114
Excess cash
3,872
3,907
8,015
Stockholders' equity
(1,895)
(2,788)
(4,426)
Invested Capital
14,259
14,216
20,164
ROIC
ROCE
EV
Common stock shares outstanding
29,350
27,967
24,880
Price
Market cap
EV
EBITDA
(3,237)
(1,657)
(5,136)
EV/EBITDA
Interest
19
61
8
Interest/NOPBT